Researchers create a new way to treat aggressive prostate cancer

A recent study, conducted by researchers at Will Cornell Medicine College, showed an unexpected role for EZH2 enzyme in promoting the growth of aggressive prostate cancer crops. EZH2 — enzyme plays an important role in regulating genetic expression in cells, by adjusting the DNA structure, and adding chemical marks known as ‘histone methyling’. This modification leads to inhibition or disruption of some genes, including genes that occur the growth of crops. In normal cases, this enzyme contributes to the regulation of cellular processes, but its excessive activity is related to the development of many types of cancer as it increases the growth of cancer cells, and helps to withstand treatments. Prostate cancer, and the results, published in the journal “Nature Communications”, provide new potential to develop treatments for patients who have limited options, and contribute to great progress to understand how advanced prostate cancer resistance to treatments and “androgen hormone” targets. One of the most important causes of cancer deaths among men. While most prostate cancer initially responds to treatments aimed at androgen receptors, some of which become an aggressive and remedial form known as “small nerve prostate cancer”. In this type of cancer, cancer cells are not dependent on androgenic signals, making their treatment a major challenge. Total crops are growing and the results have revealed that the absence of a protein called (PKCλ/ι) in prostate cancer cells enables EZH2 enzyme to increase the aggressive growth of crops, even in the presence of androgen receptors. PKCλ/ι) is one of the types of protein responsible for organizing signals in the cell, and it belongs to a family of enzymes called ‘proteininase’. This protein plays an important role in maintaining balance in the cells, including organizing its growth, division and natural functions, and also works as a brake of enzyme activity such as EZH2, which limits the ability to increase the growth of cancer crops. If this protein is absent in prostate cancer cells, the body loses one of its defense mechanisms, enabling excessive activity of enzymes that contributes to the development and distribution of cancer. New cancer treatment methods and have shown scientific experiments conducted in the laboratory, and animal models should disrupt the non -traditional functions of EZH2 enzyme can play a major role in developing new treatment methods, which means the possibility of using techniques, or drugs that rise these alternative activities of the current treatment. It has also proven that the target of this road can increase the effectiveness of immunotherapy, which is not achieved with great success if used on its own to treat prostate cancer. The researchers pointed out that the absence of protein (PKCλ/ι) creates a unique weakness in cancer cells, which opens the door for the possibility of combining EZH2 inhibitors and the treatments that target androgen receptors to effectively stop the growth of crops. However, scientists have warned that EZH2 bred in crops containing high protein levels (PKCλ/ι) could lead to reverse effects, which confirm the need to design accurate treatments that fit the condition of each patient.